Isentress licence extension

Isentress (raltegravir) can now be prescribed for treatment-naïve HIV patients. The integrase inhibitor, which must be given in combination with other antiretrovirals, is approved for use in people aged 16 years or over.

View Isentress drug record

Further information: MSD


To sign up for the MIMS monthly news update, register at www.mims.co.uk/bulletins.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Proposed withdrawal of bipolar disorder treatment revoked

Proposed withdrawal of bipolar disorder treatment revoked

The manufacturer of first-line bipolar disorder treatment...

NICE recommends further migraine prevention option

NICE recommends further migraine prevention option

Galcanezumab (Emgality) is the second calcitonin gene-related...